<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39413068</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The effect of corticosteroids in developing active pulmonary tuberculosis among patients with COVID-19.</ArticleTitle><Pagination><StartPage>e0309392</StartPage><MedlinePgn>e0309392</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0309392</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0309392</ELocationID><Abstract><AbstractText>Corticosteroids can reduce the mortality rate among patients with severe COVID-19 pneumonia. However, opportunistic infections such as Mycobacterium tuberculosis are of concern, especially among those on high doses of corticosteroids. It is unknown whether the risk of developing subsequent TB infection is high or not among COVID-19 patients on high doses of corticosteroids. Hence, this study was conducted to address this gap of knowledge. We conducted a retrospective, cross-sectional study at the King Chulalongkorn Memorial Hospital from October 12, 2022 to June 30, 2023. Two hundred forty-three participants with documented COVID-19 diagnosis on high dose corticosteroids were enrolled into the study. Baseline characteristics and risk factors of developing TB were collected. The prevalence of TB was significantly different among participants with chronic kidney disease (CKD) stages 2-4 and chronic lung diseases. The incidence of TB post 1-year diagnosis of COVID-19 was 4 out of 243 patients (1.6%) or 1,646 cases per 100,000 person-year. The mortality rate among subsequent TB group was significantly much higher than the non-TB group (50% vs 0.4%; p-value = 0.001). COVID-19 participants on high doses of corticosteroids also were co-infected with other infections such as bacteria (37.1%), fungi (5.3%), and Pneumocystis jirovecii (PJP) (1.2%). We found that the incidence of TB in participants with COVID-19 on high doses of corticosteroids was 11 times higher than the general population. Therefore, we recommend screening for latent TB among these patients to prevent/early diagnose TB disease.</AbstractText><CopyrightInformation>Copyright: © 2024 Praphakornmano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Praphakornmano</LastName><ForeName>Thanas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torvorapanit</LastName><ForeName>Pattama</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9507-6339</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emerging Infectious Diseases Clinical Center, Thai Red Cross Society, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siranart</LastName><ForeName>Noppachai</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3315-6020</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohata</LastName><ForeName>Pirapon June</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0001-6067-3707</Identifier><AffiliationInfo><Affiliation>HIV-NAT, Thai Red Cross-AIDS Research Centre, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwanpimolkul</LastName><ForeName>Gompol</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5199-7440</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emerging Infectious Diseases Clinical Center, Thai Red Cross Society, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014397" MajorTopicYN="Y">Tuberculosis, Pulmonary</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="Y">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39413068</ArticleId><ArticleId IdType="pmc">PMC11482670</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0309392</ArticleId><ArticleId IdType="pii">PONE-D-24-12295</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization Global Tuberculosis Report 2021: World Health Organization [Available from: https://apps.who.int/iris/rest/bitstreams/1379788/retrieve.</Citation></Reference><Reference><Citation>COVID-19 Coronavirus Pandemic Reported Cases and Deaths: WORLDOMETER; [Available from: https://www.worldometers.info/coronavirus/.</Citation></Reference><Reference><Citation>Liu BM, Hill HR. Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review. J Interferon Cytokine Res. 2020;40(12):549–54. doi: 10.1089/jir.2020.0210</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2020.0210</ArticleId><ArticleId IdType="pmc">PMC7757688</ArticleId><ArticleId IdType="pubmed">33337932</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu BM, Martins TB, Peterson LK, Hill HR. Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review. Cytokine. 2021;142:155478. doi: 10.1016/j.cyto.2021.155478</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155478</ArticleId><ArticleId IdType="pmc">PMC7901304</ArticleId><ArticleId IdType="pubmed">33667962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolilekas L, Loverdos K, Giannakaki S, Vlassi L, Levounets A, Zervas E, et al.. Can steroids reverse the severe COVID-19 induced "cytokine storm"? J Med Virol. 2020;92(11):2866–9. doi: 10.1002/jmv.26165</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26165</ArticleId><ArticleId IdType="pmc">PMC7307112</ArticleId><ArticleId IdType="pubmed">32530507</ArticleId></ArticleIdList></Reference><Reference><Citation>Siranart N, Sowalertrat W, Sukonpatip M, Suwanpimolkul G, Torvorapanit P. First case series and literature review of coronavirus disease 2019 (COVID-19) associated pulmonary tuberculosis in Southeast Asia: Challenges and opportunities. J Infect Public Health. 2023;16(1):80–9. doi: 10.1016/j.jiph.2022.11.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.11.029</ArticleId><ArticleId IdType="pmc">PMC9707022</ArticleId><ArticleId IdType="pubmed">36495816</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadolini M, Codecasa LR, Garcia-Garcia JM, Blanc FX, Borisov S, Alffenaar JW, et al.. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020;56(1). doi: 10.1183/13993003.01398-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01398-2020</ArticleId><ArticleId IdType="pmc">PMC7251245</ArticleId><ArticleId IdType="pubmed">32457198</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalaswamy R, Subbian S. Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis. Int J Mol Sci. 2021;22(7). doi: 10.3390/ijms22073773</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22073773</ArticleId><ArticleId IdType="pmc">PMC8038708</ArticleId><ArticleId IdType="pubmed">33917321</ArticleId></ArticleIdList></Reference><Reference><Citation>Obata R, Maeda T, Rizk D, Kuno T. Increased Secondary Infection in COVID-19 Patients Treated with Steroids in New York City. Jpn J Infect Dis. 2021;74(4):307–15. doi: 10.7883/yoken.JJID.2020.884</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2020.884</ArticleId><ArticleId IdType="pubmed">33390434</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CC, Lee MT, Lee SH, Lee SH, Chang SS, Lee CC. Risk of incident active tuberculosis and use of corticosteroids. Int J Tuberc Lung Dis. 2015;19(8):936–42. doi: 10.5588/ijtld.15.0031</Citation><ArticleIdList><ArticleId IdType="doi">10.5588/ijtld.15.0031</ArticleId><ArticleId IdType="pubmed">26162360</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–63. doi: 10.1093/clinids/11.6.954</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/11.6.954</ArticleId><ArticleId IdType="pubmed">2690289</ArticleId></ArticleIdList></Reference><Reference><Citation>Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221–47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764341</ArticleId></ArticleIdList></Reference><Reference><Citation>Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18(1):1. doi: 10.1186/s40360-016-0111-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40360-016-0111-8</ArticleId><ArticleId IdType="pmc">PMC5216559</ArticleId><ArticleId IdType="pubmed">28057083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai JW, Ruan QL, Liu QH, Zhang WH. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5(2):e10. doi: 10.1038/emi.2016.10</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2016.10</ArticleId><ArticleId IdType="pmc">PMC4777925</ArticleId><ArticleId IdType="pubmed">26839146</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumwichar P, Chongsuvivatwong V. COVID-19 pneumonia and the subsequent risk of getting active pulmonary tuberculosis: a population-based dynamic cohort study using national insurance claims databases. EClinicalMedicine. 2023;56:101825. doi: 10.1016/j.eclinm.2023.101825</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101825</ArticleId><ArticleId IdType="pmc">PMC9854255</ArticleId><ArticleId IdType="pubmed">36694864</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuberculosis profile: Thailand: TBThailand.org; [Available from: https://www.tbthailand.org/statustb.html.</Citation></Reference><Reference><Citation>Nabity SA, Marks SM, Goswami ND, Smith SR, Timme E, Price SF, et al.. Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States. Emerg Infect Dis. 2023;29(10):2016–23. doi: 10.3201/eid2910.230286</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2910.230286</ArticleId><ArticleId IdType="pmc">PMC10521611</ArticleId><ArticleId IdType="pubmed">37647628</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Totten M, Nematollahi S, Datta K, Memon W, Marimuthu S, et al.. Development and Evaluation of a Fully Automated Molecular Assay Targeting the Mitochondrial Small Subunit rRNA Gene for the Detection of Pneumocystis jirovecii in Bronchoalveolar Lavage Fluid Specimens. J Mol Diagn. 2020;22(12):1482–93. doi: 10.1016/j.jmoldx.2020.10.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmoldx.2020.10.003</ArticleId><ArticleId IdType="pubmed">33069878</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al.. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–76. doi: 10.1093/cid/ciz1008</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz1008</ArticleId><ArticleId IdType="pmc">PMC7486838</ArticleId><ArticleId IdType="pubmed">31802125</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>